Balaxi Pharmaceuticals Board Meeting Outcome

Balaxi Pharmaceuticals Q2 FY27 Results: Net Profit ₹1.2 Cr, Up 500.0% YoY

Balaxi Pharmaceuticals Ltd reported revenue from operations of ₹81.4 Cr (+44.8% YoY) and net profit of ₹1.2 Cr (+500.0% YoY) for Q2 FY27.

Key figure

Net profit ₹1.2 Cr · +500.0% YoY

Balaxi Pharmaceuticals Other Announcement

Balaxi Pharmaceuticals filed its RTA report for October 2026 on re-lodgement of physical share transfers. All request counts for the month are NIL.

Balaxi Pharmaceuticals Board Meeting Date

Balaxi Pharmaceuticals will meet on 12 November 2026 to approve unaudited half-year results. The trading window stays closed until 14 November 2026.

Balaxi Pharmaceuticals Other Announcement

Balaxi Pharmaceuticals Limited reported nil activity regarding the re-lodgement of physical share transfer requests for the period ended September 2026.

Balaxi Pharmaceuticals Other Announcement

Balaxi Pharmaceuticals reported nil activity regarding the re-lodgement of physical share transfer requests for August 2026. This is a routine regulatory compliance filing.

Balaxi Pharmaceuticals Business Update

Balaxi Pharmaceuticals has received WHO-GMP certification for its first pharmaceutical formulation manufacturing facility in Telangana. The facility has commenced manufacturing initially approved products for international markets.

Ennature Bio Pharma Board Meeting Outcome

Ennature Bio Pharma's board approved adoption of new Articles of Association to align with SCRA Rules 1957 and group governance. The change is subject to shareholder approval.

Shri Keshav Cements & Infra Board Meeting Outcome

Shri Keshav Cements' board approved un-audited financial and segment-wise revenue results for the quarter and half-year ended 30 September 2026. No other material decisions were transacted.

Balmer Lawrie Investments Board Meeting Outcome

Balmer Lawrie Investments appointed M/s. K. K. Chanani & Associates as Statutory Auditor for FY 2026-27 under Section 139(5), per a C&AG letter. The appointment is effective from 10 November 2026.

Execution

FY 2026-27

Jiwanram Sheoduttrai Industries Board Meeting Outcome

Jiwanram Sheoduttrai's board approved convening its 29th AGM on 30 November 2026 and re-appointing a retiring non-executive director. The board also approved the FY2025-26 Board's Report.

Finolex Cables Board Meeting Outcome

Finolex Cables' board approved amending its insider trading code of conduct on 7 November 2026. Amended code was filed under PIT Regulation 8(2).

Chatterbox Technologies Board Meeting Outcome

Chatterbox's board approved a Rs. 7 crore related-party ceiling with its UAE subsidiary and a vendor change for IPO funds. Monitoring agency and deviation reports were also noted.